Cargando…

Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines

Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector–vector versus heterologous, vector–mRNA), the influence of vaccination side effects, and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerhards, Catharina, Thiaucourt, Margot, Hetjens, Michael, Haselmann, Verena, Neumaier, Michael, Kittel, Maximilian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054089/
https://www.ncbi.nlm.nih.gov/pubmed/36992285
http://dx.doi.org/10.3390/vaccines11030701
_version_ 1785015571314638848
author Gerhards, Catharina
Thiaucourt, Margot
Hetjens, Michael
Haselmann, Verena
Neumaier, Michael
Kittel, Maximilian
author_facet Gerhards, Catharina
Thiaucourt, Margot
Hetjens, Michael
Haselmann, Verena
Neumaier, Michael
Kittel, Maximilian
author_sort Gerhards, Catharina
collection PubMed
description Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector–vector versus heterologous, vector–mRNA), the influence of vaccination side effects, and the infection rate in German healthcare workers need to be investigated. Methods: In this study, 103 individuals vaccinated against SARS-CoV-2 were enrolled to examine their anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig levels. A total of 415 blood samples in lithium heparin tubes were prospectively obtained, and a structured survey regarding medical history, type of vaccine, and vaccination reactions was conducted. Results: All participants demonstrated a humoral immune response, among whom no values decreased below the positivity cutoff. Five to six months after the third vaccination, three participants showed anti-RBD/S1 antibodies of less than 1000 U/mL. We observed higher levels for heterologous mRNA-/vector-based combinations compared to pure vector-based vaccination after the second vaccination, which is harmonized after a third vaccination with the mRNA-vaccine only in both cohorts. The incidence of vaccine breakthrough in a highly exposed cohort was 60.3%. Conclusion: Sustained long-term humoral immunity was observed, indicating the superiority of a heterologous mRNA-/vector-based combination compared to pure vector-based vaccination. There was longevity of anti-RBD/S1 antibodies of at least 4 and up to 7 months without external stimulus. Regarding vaccination reactogenity, the occurrence of local symptoms as pain at the injection site was increased after the first mRNA application compared to the vector–vector cohort with a general decrease in adverse events at later vaccination time points. Overall, a correlation between the humoral vaccination response and vaccination side effects was not observed. Despite the high prevalence of vaccine breakthroughs, these only occurred in the later course of the study when more infectious variants, which are, however, associated with milder courses, were present. These results provide insights into vaccine-related serologic responses, and the study should be expanded using additional vaccine doses and novel variants in the future.
format Online
Article
Text
id pubmed-10054089
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100540892023-03-30 Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines Gerhards, Catharina Thiaucourt, Margot Hetjens, Michael Haselmann, Verena Neumaier, Michael Kittel, Maximilian Vaccines (Basel) Article Background: Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector–vector versus heterologous, vector–mRNA), the influence of vaccination side effects, and the infection rate in German healthcare workers need to be investigated. Methods: In this study, 103 individuals vaccinated against SARS-CoV-2 were enrolled to examine their anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig levels. A total of 415 blood samples in lithium heparin tubes were prospectively obtained, and a structured survey regarding medical history, type of vaccine, and vaccination reactions was conducted. Results: All participants demonstrated a humoral immune response, among whom no values decreased below the positivity cutoff. Five to six months after the third vaccination, three participants showed anti-RBD/S1 antibodies of less than 1000 U/mL. We observed higher levels for heterologous mRNA-/vector-based combinations compared to pure vector-based vaccination after the second vaccination, which is harmonized after a third vaccination with the mRNA-vaccine only in both cohorts. The incidence of vaccine breakthrough in a highly exposed cohort was 60.3%. Conclusion: Sustained long-term humoral immunity was observed, indicating the superiority of a heterologous mRNA-/vector-based combination compared to pure vector-based vaccination. There was longevity of anti-RBD/S1 antibodies of at least 4 and up to 7 months without external stimulus. Regarding vaccination reactogenity, the occurrence of local symptoms as pain at the injection site was increased after the first mRNA application compared to the vector–vector cohort with a general decrease in adverse events at later vaccination time points. Overall, a correlation between the humoral vaccination response and vaccination side effects was not observed. Despite the high prevalence of vaccine breakthroughs, these only occurred in the later course of the study when more infectious variants, which are, however, associated with milder courses, were present. These results provide insights into vaccine-related serologic responses, and the study should be expanded using additional vaccine doses and novel variants in the future. MDPI 2023-03-19 /pmc/articles/PMC10054089/ /pubmed/36992285 http://dx.doi.org/10.3390/vaccines11030701 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gerhards, Catharina
Thiaucourt, Margot
Hetjens, Michael
Haselmann, Verena
Neumaier, Michael
Kittel, Maximilian
Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
title Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
title_full Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
title_fullStr Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
title_full_unstemmed Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
title_short Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
title_sort heterologous vector—mrna based sars-cov-2 vaccination strategy appears superior to a homologous vector—based vaccination scheme in german healthcare workers regarding humoral sars-cov-2 response indicating a high boosting effect by mrna vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054089/
https://www.ncbi.nlm.nih.gov/pubmed/36992285
http://dx.doi.org/10.3390/vaccines11030701
work_keys_str_mv AT gerhardscatharina heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines
AT thiaucourtmargot heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines
AT hetjensmichael heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines
AT haselmannverena heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines
AT neumaiermichael heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines
AT kittelmaximilian heterologousvectormrnabasedsarscov2vaccinationstrategyappearssuperiortoahomologousvectorbasedvaccinationschemeingermanhealthcareworkersregardinghumoralsarscov2responseindicatingahighboostingeffectbymrnavaccines